Scleroderma Clinical Trial
Official title:
A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with scleroderma-associated digital ulcers
This clinical trial is a US, multicenter, double-blind, randomized placebo-controlled,
parallel- group study with a total of 20 participants planned to be randomized (approximately
10 participants to the riociguat group and 10 to the placebo group). In addition, a
standardized wound care protocol will be followed by the investigators and digital
photography will be taken of the cardinal ulcer.
The study will allow standard of care medications for the management of DU as background
therapy. These may include calcium channel blockers, low dose aspirin, angiotensin enzyme
inhibitors, etc. and will be determined by the participant's local physician.
The study design consists of three phases:
- Screening phase: up to 2 weeks
- Double-blind Treatment phase: 16 weeks of double-blind treatment, consisting of:
- Dose titration period of up to 8 weeks, and
- Stable dosing period of up to 8 weeks
- Open-label Extension phase for participants with active DU at the end of the double-
blind treatment phase or development of an active DU within a month of completing
double-blind phase, consisting of:
- Dose titration phase of up to 8 weeks
- Stable dosing period for 8 weeks
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02798055 -
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
|
||
| Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
| Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01895244 -
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT00930683 -
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
|
Phase 1 | |
| Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
| Completed |
NCT00074568 -
Scleroderma Registry
|
||
| Recruiting |
NCT04797286 -
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
|
Phase 2 | |
| Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03207997 -
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
|
N/A | |
| Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
| Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A | |
| Completed |
NCT05080738 -
Upper Extremity Home Exercises in Patients With Scleroderma
|
N/A | |
| Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
| Completed |
NCT02062125 -
Calcinosis in a Single-Center Scleroderma Population
|
||
| Completed |
NCT04588714 -
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02835196 -
Optical Elastography of Systemic Sclerosis Skin
|
||
| Completed |
NCT02896205 -
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
|
Phase 3 |